Abstract
Elucidation of the molecular pathways underlying bone turnover has revealed potential therapeutic targets, including receptor activator of nuclear factor-κB ligand (RANKL), which is a mediator of osteoclast formation, function and survival. Denosumab is a fully human monoclonal antibody that binds to and inhibits RANKL. This agent has been developed for use in patients with early-stage and advanced-stage cancer, as well as for the treatment of osteoporosis, and can prevent bone loss and reduce fragility fractures in both types of disease. In the bone metastasis setting, several large phase III studies have shown that denosumab is more effective than bisphosphonates, namely zoledronic acid, in reducing skeletal morbidity arising from a wide range of tumors. In addition, a remarkable activity of denosumab has been demonstrated in giant-cell tumors of the bone. Subsequent studies of denosumab have demonstrated that it can delay bone metastasis in patients with castration-resistant prostate cancer; adjuvant studies in patients with breast cancer are in progress. This Review critically explores the emerging role of denosumab in maintaining bone health in the oncology setting, and discusses the factors that are likely to influence the choice between bisphosphonates and denosumab in clinical practice.
Key Points
-
Denosumab, a human monoclonal antibody, inhibits receptor activator of nuclear factor-κB ligand (RANKL), which mediates the increased bone resorption resulting from bone metastasis and cancer treatment
-
Phase III trials in patients with bone metastases of breast cancer, prostate cancer and other solid tumors demonstrated the superiority of denosumab over zoledronic acid in reducing skeletal morbidity
-
A strong antitumor response has been observed in phase II studies of denosumab in giant-cell tumors of bone
-
Denosumab is less likely than zoledronic acid to induce renal toxic effects and acute-phase reactions, but both drugs are associated with similar incidence of osteonecrosis of the jaw
-
Depending on the cost, denosumab could become widely used in the management of bone health in oncology
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lipton, A. New approaches to treating and preventing bone metastases. Curr. Opin. Support. Palliat. Care 4, 178–181 (2010).
Coleman, R. E. et al. Metastasis and bone loss; advancing treatment and prevention. Cancer Treat. Rev. 36, 615–620 (2010).
Guise, T. Examining the metastatic niche: targeting the microenvironment. Semin. Oncol. 37 (Suppl. 2), S2–S14 (2010).
Casimiro, S., Guise, T. A. & Chirgwin, J. The critical role of the bone microenvironment in cancer metastases. Mol. Cell. Endocrinol. 310, 71–81 (2009).
Guise, T. A. Brufsky, A. & Coleman, R. E. Understanding and optimizing bone health in breast cancer. Curr. Med. Res. Opin. 26 (Suppl. 3), 3–20 (2010).
Coleman, R. E. & McCloskey, E. V. Bisphosphonates in oncology. Bone 49, 71–76 (2011).
Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337–342 (2003).
Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315–323 (1998).
Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309–319 (1997).
Canon, J. R. et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin. Exp. Metastasis 25, 119–129 (2008).
Dougall, W. C. & Chaisson, M. The RANK/RANKL/OPG triad in cancer induced bone diseases. Cancer Metastasis Rev. 25, 541–549 (2006).
Kitazawa, S. & Kitazawa, R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J. Pathol. 198, 228–236 (2002).
Akiyama, T., Choong, P. F. & Dass, C. R. RANK–Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells. Clin. Exp. Metastasis 27, 207–215 (2010).
Akiyama, T. et al. Systemic RANK–Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts. J. Pharm. Pharmacol. 62, 470–476 (2010).
Mori, K. et al. DU145 human prostate cancer cells express functional receptor of NFκB: new insights in the prostate cancer bone metastasis process. Bone 40, 981–990 (2007).
Jones, D. H. et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692–696 (2006).
Tan, W. et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling. Nature 470, 548–553 (2011).
Fata, J. E. et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41–50 (2000).
Gonzalez-Suarez, E. et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468, 103–107 (2010).
Schramek, D. et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468, 98–102, (2010).
Lipton, A. et al. Markers of bone resorption in patients treated with pamidronate. Eur. J. Cancer 34, 2021–2026 (1998).
Brown, J. E. et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl Cancer Inst. 97, 59–69 (2005).
Coleman, R. E. et al. The predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 23, 4925–4935 (2005).
Body, J. J. et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 (Suppl. 3), 887–892 (2003).
Holen, I. et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo—a role in tumour cell survival? Breast Cancer Res. Treat. 92, 207–215 (2005).
Bekker, P. J. et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL in postmenopausal women. J. Bone Miner. Res. 19, 1059–1066 (2004).
Body, J. J. et al. Study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Cancer Res. 12, 1221–1228 (2006).
Lipton, A. et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J. Clin. Oncol. 25, 4431–4437 (2007).
Bone, H. G. et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J. Clin. Endocrinol. Metab. 93, 2149–2157 (2008).
Ellis, G. K. et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. J. Clin. Oncol. 26, 4875–4882 (2008).
Oefelein, M. G., Ricchiuti, V., Conrad, W. & Resnick, M. I. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J. Urol. 168, 1005–1007 (2002).
Shahinian, V. B., Kuo, Y. F., Freeman, J. L. & Goodwin, J. S. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352, 154–164 (2005).
Smith, M. R. et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J. Urol. 175, 136–139 (2006).
Smith, M. R. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745–755 (2009).
Gnant, M. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 12, 631–641 (2011).
Coleman, R. E. et al. Breast cancer adjuvant therapy with and without zoledronic acid. N. Engl. J. Med. 365, 1396–1405 (2011).
US National Library of Medicine. ClinicalTrials.gov [online].
Smith, M. R. et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase III, randomised, placebo-controlled trial Lancet http://dx.doi.org/10.1016/S0140-6736(11)61226-9.
Fizazi, K. et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol. 27, 1564–1571 (2009).
Stopeck, A. T. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132–5139 (2010).
Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813–822 (2011).
Henry, D. H. et al. A randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29, 1125–1132 (2011).
Lipton, A., Comparison of denosumab versus zoledronic acid (ZA) for treatment of bone metastases in advanced cancer patients: an integrated analysis of 3 pivotal trials [abstract]. Ann. Oncol. 21 (Suppl. 8), viii380 (2010).
Fallowfield, L. et al. Effects of denosumab versus zoledronic acid (ZA) on health-related quality of life (HRQL) in metastatic breast cancer: results from a randomized phase III trial [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a1025 (2010).
Heath, D. J. et al. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res. 67, 202–208 (2007).
Vij, R. et al. An open-label, phase II trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am. J. Hematol. 84, 650–656 (2009).
US National Library of Medicine. ClinicalTrials.gov [online].
Huang, L., Xu, J., Wood, D. J. & Zheng, M. H. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-κB in giant cell tumour of bone: possible involvement in tumour cell-induced osteoclast-like cell formation. Am. J. Pathol. 156, 761–767 (2000).
Turcotte, R. E., Giant cell tumour of bone. Orthop. Clin. North. Am. 37, 35–51 (2006).
Thomas, D. et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase II study. Lancet Oncol. 11, 275–280 (2010).
Saad, F. et al. Incidence, risk factors and outcomes of osteonecrosis of the jaw: integrated analysis from 3 blinded, active-controlled phase III trials in cancer patients with bone metastases. Ann. Oncol. http://dx.doi.org/10.1093/annonc/mdr435.
Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J. Oral Maxillofac. Surg. 67 (Suppl. 5), 2–12 (2009).
Coleman, R. E. et al. Zoledronic acid. Expert Opin. Drug Saf. 10, 133–145 (2011).
Yu, E. Y. et al. Phase II study of dasatinib in patients with metastatic castration resistant prostate cancer. Clin. Cancer Res. 15, 7421–7428 (2009).
Gucalp, A. et al. Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin. Breast Cancer 5, 306–311 (2011).
Nilsson, S. et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 8, 587–594 (2007).
Parker, C. et al. Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomised trial (ALSYMPCA) [abstract]. Eur. J. Cancer 47 (Suppl. 2), a3 (2011).
Roodman, G. D. Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655–1664 (2004).
Mundy, G. R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584–593 (2002).
Acknowledgements
J. E. Brown has been awarded a Clinician Scientist Fellowship by Cancer Research UK.
Author information
Authors and Affiliations
Contributions
Both authors contributed to all aspects of the article, including researching data, discussion of content, and writing, reviewing and editing the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
J. E. Brown declares that she is a consultant for and has received honoraria from Amgen. She has also received honoraria and grant funding from Novartis. R. E. Coleman declares that he is a consultant for and has received honoraria and grant funding from Novartis. He has also received honoraria from Amgen.
Rights and permissions
About this article
Cite this article
Brown, J., Coleman, R. Denosumab in patients with cancer—a surgical strike against the osteoclast. Nat Rev Clin Oncol 9, 110–118 (2012). https://doi.org/10.1038/nrclinonc.2011.197
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.197
This article is cited by
-
Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
BMC Musculoskeletal Disorders (2022)
-
Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease
Nature Communications (2022)
-
Recent advances in the targeted fluorescent probes for the detection of metastatic bone cancer
Science China Chemistry (2021)
-
Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany
Supportive Care in Cancer (2020)
-
Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment
Scientific Reports (2019)